Related Experiment Video
Updated: Jul 8, 2026
09:12
Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
Published on: June 14, 2024
Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies
D E Spaner1, R Foley, J Galipeau
1Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women's College Health Sciences Center, Toronto, Canada. david.spaner@swri.ca
Oncogene
|January 8, 2008
Summary
Microbial products show promise for treating hematologic malignancies by activating Toll-like receptors (TLRs). Combining TLR agonists with agents that overcome tumor microenvironment inhibition may enhance efficacy for systemic diseases.
Area of Science:
- Immunology
- Oncology
- Microbiology
Background:
- Microbial products exhibit clinical activity against hematologic malignancies.
- Toll-like receptors (TLRs) activated by microbial ligands are implicated in this activity.
- TLR agonists can induce tumor cell differentiation, increasing sensitivity to therapies.
Purpose of the Study:
- To explore the role of TLRs in the anti-cancer activity of microbial products.
- To investigate mechanisms by which TLR agonists enhance anti-leukemia/lymphoma effects.
- To identify strategies for improving TLR agonist efficacy against systemic hematologic malignancies.
Main Methods:
- Review of recent advances in TLR signaling and cancer therapy.
- Analysis of the impact of the tumor microenvironment on TLR agonist effectiveness.
- Hypothesizing combined treatment strategies for hematologic malignancies.
Main Results:
- TLR agonists show efficacy against cutaneous leukemias and lymphomas.
- Systemic disease treatment is less effective, potentially due to the tumor microenvironment.
- Hypoxia, suppressive cytokines, prostaglandins, and nucleosides inhibit TLR signaling in cancer cells.
Conclusions:
- TLR agonists represent a promising therapeutic avenue for hematologic malignancies.
- Overcoming tumor microenvironment-mediated inhibition is crucial for systemic treatment.
- Combined therapy with TLR agonists and agents targeting microenvironmental factors may improve outcomes.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...